Notice Regarding Submission of New Drug Application (NDA) for F351 in China for the Treatment for Chronic Hepatitis B Induced Liver Fibrosis3/24TDnetPDF(247KB)
Announcement of Priority Review Designation by China's NMPA for F351, a Treatment for Chronic Hepatitis B Induced Liver Fibrosis3/18TDnetPDF(113KB)
Disclosure of Statements Made at an Investor Conference of Gyre Therapeutics, Inc.3/13TDnetPDF(142KB)
(Correction of Numerical Data) Partial Correction to the“Consolidated Financial Results for FY 2025 (IFRS)”3/4TDnetPDF(693KB)
Notice Regarding the Execution of an Agreement for the Acquisition of Cullgen Inc. by Consolidated Subsidiary Gyre Therapeutics, Inc.3/3TDnetPDF(4MB)
Notice Regarding the Postponement of the Disclosure of FY2026 Consolidated Earnings Forecast and Earnings Briefing2/13TDnetPDF(242KB)
Notice Regarding Differences in Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 and the Previous Fiscal Year 2/13TDnetPDF(134KB)
Announcement Regarding Revision of Full-Year Earnings Forecast and Expected Recognition of Losses1/23TDnetPDF(148KB)